These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23856031)

  • 1. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
    Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
    Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Human-Derived
    Schubert L; Le AT; Estrada-Bernal A; Doak AE; Yoo M; Ferrara SE; Goodspeed A; Kinose F; Rix U; Tan AC; Doebele RC
    Mol Pharmacol; 2021 Jun; 99(6):435-447. PubMed ID: 33795352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.
    Chen ZH; Yu YP; Tao J; Liu S; Tseng G; Nalesnik M; Hamilton R; Bhargava R; Nelson JB; Pennathur A; Monga SP; Luketich JD; Michalopoulos GK; Luo JH
    Gastroenterology; 2017 Oct; 153(4):1120-1132.e15. PubMed ID: 28245430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor Activity of RXDX-105 in Multiple Cancer Types with
    Li GG; Somwar R; Joseph J; Smith RS; Hayashi T; Martin L; Franovic A; Schairer A; Martin E; Riely GJ; Harris J; Yan S; Wei G; Oliver JW; Patel R; Multani P; Ladanyi M; Drilon A
    Clin Cancer Res; 2017 Jun; 23(12):2981-2990. PubMed ID: 28011461
    [No Abstract]   [Full Text] [Related]  

  • 5. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway.
    Lin C; Wang S; Xie W; Zheng R; Gan Y; Chang J
    Oncotarget; 2016 Sep; 7(37):59236-59244. PubMed ID: 27494860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective RET kinase inhibition for patients with RET-altered cancers.
    Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
    Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
    Lipson D; Capelletti M; Yelensky R; Otto G; Parker A; Jarosz M; Curran JA; Balasubramanian S; Bloom T; Brennan KW; Donahue A; Downing SR; Frampton GM; Garcia L; Juhn F; Mitchell KC; White E; White J; Zwirko Z; Peretz T; Nechushtan H; Soussan-Gutman L; Kim J; Sasaki H; Kim HR; Park SI; Ercan D; Sheehan CE; Ross JS; Cronin MT; Jänne PA; Stephens PJ
    Nat Med; 2012 Feb; 18(3):382-4. PubMed ID: 22327622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.
    Frett B; Carlomagno F; Moccia ML; Brescia A; Federico G; De Falco V; Admire B; Chen Z; Qi W; Santoro M; Li HY
    Angew Chem Int Ed Engl; 2015 Jul; 54(30):8717-21. PubMed ID: 26126987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC.
    Shiba-Ishii A; Isagawa T; Shiozawa T; Mato N; Nakagawa T; Takada Y; Hirai K; Hong J; Saitoh A; Takeda N; Niki T; Murakami Y; Matsubara D
    Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167249. PubMed ID: 38768929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.
    Plenker D; Riedel M; Brägelmann J; Dammert MA; Chauhan R; Knowles PP; Lorenz C; Keul M; Bührmann M; Pagel O; Tischler V; Scheel AH; Schütte D; Song Y; Stark J; Mrugalla F; Alber Y; Richters A; Engel J; Leenders F; Heuckmann JM; Wolf J; Diebold J; Pall G; Peifer M; Aerts M; Gevaert K; Zahedi RP; Buettner R; Shokat KM; McDonald NQ; Kast SM; Gautschi O; Thomas RK; Sos ML
    Sci Transl Med; 2017 Jun; 9(394):. PubMed ID: 28615362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The action and resistance mechanisms of Lenvatinib in liver cancer.
    Buttell A; Qiu W
    Mol Carcinog; 2023 Dec; 62(12):1918-1934. PubMed ID: 37671815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCDC6-RET fusion protein regulates Ras/MAPK signaling through the fusion- GRB2-SHC1 signal niche.
    Qiu T; Kong Y; Wei G; Sun K; Wang R; Wang Y; Chen Y; Wang W; Zhang Y; Jiang C; Yang P; Xie T; Chen X
    Proc Natl Acad Sci U S A; 2024 Jun; 121(23):e2322359121. PubMed ID: 38805286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers.
    Cheong TC; Jang A; Wang Q; Leonardi GC; Ricciuti B; Alessi JV; Di Federico A; Awad MM; Lehtinen MK; Harris MH; Chiarle R
    Nat Commun; 2024 Jun; 15(1):5110. PubMed ID: 38877018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases.
    Hu X; Liu X; Khatri U; Wu J
    Drug Resist Updat; 2023 May; 68():100958. PubMed ID: 36990046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabrafenib alleviates hepatotoxicity caused by lenvatinib via inhibiting the death receptor signaling pathway.
    Tao X; Cheng M; Huang X; Chen J; Zhou Y; Liu T; Zheng X; Shen N; Zhang Y; Luo P; He Q; Yan H; Huang P
    Toxicol Lett; 2024 Jun; 397():163-173. PubMed ID: 38754640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyzing Somatic Genome Rearrangements in Human Cancers by Using Whole-Exome Sequencing.
    Yang L; Lee MS; Lu H; Oh DY; Kim YJ; Park D; Park G; Ren X; Bristow CA; Haseley PS; Lee S; Pantazi A; Kucherlapati R; Park WY; Scott KL; Choi YL; Park PJ
    Am J Hum Genet; 2016 May; 98(5):843-856. PubMed ID: 27153396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.
    Frett B; Moccia M; Carlomagno F; Santoro M; Li HY
    Eur J Med Chem; 2014 Oct; 86():714-23. PubMed ID: 25232968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET in breast cancer: functional and therapeutic implications.
    Morandi A; Plaza-Menacho I; Isacke CM
    Trends Mol Med; 2011 Mar; 17(3):149-57. PubMed ID: 21251878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies and Recent Advances on Improving Efficient Antitumor of Lenvatinib Based on Nanoparticle Delivery System.
    Wang H; Bo W; Feng X; Zhang J; Li G; Chen Y
    Int J Nanomedicine; 2024; 19():5581-5603. PubMed ID: 38882543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Caged Ret Kinase Inhibitor and its Effect on Motoneuron Development in Zebrafish Embryos.
    Bliman D; Nilsson JR; Kettunen P; Andréasson J; Grøtli M
    Sci Rep; 2015 Aug; 5():13109. PubMed ID: 26300345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.